Omega-3 polyunsaturated fatty acids in early undifferentiated peripheral arthritis

Objective: to study the effect of a drug of omega-3 polyunsaturated fatty acids (omega-3 PUFA) in patients with early undifferentiated peripheral arthritis (UPA) on the development of rheumatoid arthritis (RA), the induction of remission, the use of disease-modifying antirheumatic drugs (DMARDs), the immunological manifestations of the disease during a 12-week follow-up. Subjects and methods. The study enrolled 40 patients with UPA and a symptom duration of less than 12 months, who took nonsteroidal anti-inflamma tory drugs (NSAIDs) and omega-3 PUFA (Vitrum Cardio Omega-3) as one capsule twice daily for 12 weeks. A control group comprised 20 patients with UPA receiving therapy with NSAIDs for 3 months. The groups did not differ significantly (p > 0.05) in age (42.98±10.81 and 48.25±13.92 years), the duration of symptoms (6.73±2.81 and 5.95±2.54 months), the number of patients positive for rheumatoid factor [14 (35%) and 7 (35%)] and antibodies to cyclic citrullinated peptide [9 (22.5%) and 7 (35%)] patients, the duration of morning stiffness (35.6±25.82 and 37.0±19.15 min), the number of swollen (3.08±1.39 and 3.30±1.21) and tender (3.63±1.63 and 3.85±1.69) joints, and DAS 28 (4.21±0.65 and 4.35±0.63). Results. The use of omega-3 PUFA did not affect significantly the incidence of RA and the use of DMARDs. Clinical remission and low DAS28 were considerably observed in the study group patients, but no statistical significance was achieved. The dose of NSAIDs, including on-demand drugs, was decreased in 22 (55%) and 4 (20%) patients in the study and control groups, respectively (p = 0.013). At 12 weeks, the study group showed signifi cant reductions in the number of tender joints, the duration of morning stiffness, erythrocyte sedimentation rate, DAS 28, and interleukin 6 levels (p < 0.05); no significant changes were found in the control group. There were no significant differences in the frequency of undesirable events. Conclusion. Omega-3 PUFAs contribute to the control of the activity of an inflammatory process, show some immunomodulatory properties, and can optimize the use of NSAIDs in patients with early UPA.

rheumatoid arthritis, undifferentiated peripheral arthritis, omge-3 polyunsaturated fatty acids

1. <div><p>Горячев Д.В., Эрдес Ш.Ф. Стоимость ревматоидного артрита и экономическая целесообразность терапии. Науч-практич ревматол 2001;5:58–65.</p><p>Насонов Е.Л. Ревматоидный артрит как общемедицинская проблема. Тер арх 2004;5:5–7.</p><p>Насонов Е.Л. Почему необходима ранняя диагностика и лечение ревматоидного артрита? Рус мед журн 2002;10(22):1009–14.</p><p>Иванова М.М., Каратеев Д.Е., Акимова Т.Ф. и др. Клинические варианты течения ревматоидного артрита и прогноз болезни. Клин ревматол 1994;2:5–9.</p><p>Иевлева Л.В., Сатыбалдыев А.М. Особенности ревматоидного артрита, начавшегося у лиц в возрасте 50 лет и старше. В кн.: Ревматоидный артрит. Под ред. В.А. Насоновой и В. Лайне. М.: Медицина, 1983;103–5.</p><p>Чичасова Н.В., Шехтер А.Б., Крель А.А. Эволюция морфологических проявлений синовита с начальной стадией ревматоидного артрита при различных вариантах его дальнейшего течения. Ревматология 1988;2:3–16.</p><p>Masi A.T., Feigenbaum S.L., KaplanS.B. Articular patterns in the early course of rheumatoid arthritis. Amer J Med 1983;75(Suppl. 6A):16–26.</p><p>Visser H. Early diagnosis of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005;19(1):55–72.</p><p>Каратеев Д.Е., Лучихина Е.Л., Тюрина Л.Н. и др. Ранняя диагностика ревматоидного артрита в клинической практике на современном этапе (результаты наблюдений за московской когортой больных ранним артритом в рамках программы РАДИКАЛ). Тер арх 2008;5:8–13.</p><p>Machado P., Castrejon I., KatchamartW. et al. Multinational evience-based recommendations on how to investigate and follow-up undifferentiated inflammatory arthritis: integrating systematic literature research and expert opinion of broad international panel of rheumatologists in the 3E Initiative.Ann Rheum Dis 2011;70:15–24.</p><p>Machold K.P., Landewe R., Smolen J.S. et al. The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann Rheum Dis 2010;69:495–502.</p><p>Van Dongen H., van Aken J., Lard L.R. et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthr Rheum 2007;56(5):1424–32.</p><p>Перова Н.В. Профилактика сердечно-сосудистых заболеваний: источники повышения потребления человеком омега-3-полиненасыщенных жирных кислот. Справ поликлин врача 2007;6:17–20.</p><p>Синчихин С.П., Мамиев О.Б. Применение омега-3-полиненасыщенных жирных кислот в медицинской практике. Гинекология 2009;11(4):51–5.</p><p>Caughey G.E., Mantzioris E., GibsonR.A. et al. The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr 1996;63:116–22.</p><p>Calder P.C. Polyunsaturated fatty acids and inflammatory processes: New twists in an old tale. Biochimie 2009;91:791–5.</p><p>Saso L., Valentini G., Casini M.L. et al. Inhibition of protein denaturation by fatty acids, bile salts and other natural substances: a new hypothesis for the mechanism ofaction of fish oil in rheumatic diseases. Jpn J Pharmacol 1999;79:89–99.</p><p>Ruggiero C., Lattanzio F., Lauretani F. et al. Omega-3 polyunsaturated fatty acids and immune-mediated diseases: inflammatory bowel disease and rheumatoid arthritis. Curr Pharm Des 2009;15:4135–48.</p><p>Kremer J.M., Lawrence D.A., PetrilloG.F. Effects of high-dose oil on rheumatoid arthritis after Stopping nonsteroidal antiinflammatory drugs. Clinical and immune correlates. Arthr Rheum 1995;38:1107–14.</p><p>Вермель А.Е. Применение омега3жирных кислот (рыбий жир) в клинической практике Клин мед 2005;83(10):51–7.</p><p>Bahadori B., Uitz E., Thonhofer R. et al. Оmega-3 Fatty acids infusions as adjuvant therapy in rheumatoid arthritis. J Parenter Enteral Nutr 2010;34:151–5.</p><p>Wall R., Ross R.P., Fitzgerald G.F., Stanton C. Fatty acids from fish: the antiinflammatory potential of long-chain omega-3 fatty acids. Nutr Rev 2010;68:280–9.</p><p>Arnett F.C., Edworthy S.M., Bloch D.A. et al. American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum 1988;31(3):315–24.</p><p>Combe B., Landewe R., Lukas C. et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies IncludingTherapeutics (ESCISIT). Ann Rheum Dis 2007;66:34–45.</p><p>Ревматология: Клинические рекомендации. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2010.</p><p>Лечение ревматоидного артрита: Клинические рекомендации. Под ред. Е.Л. Насонова. М., 2006.</p><p>Nishimoto N., Kishimoto T., YoshizakiK. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 2000;59(Suppl. 1):i21–i27.</p><p>Patel A.M., Moreland L.W. Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Des Devel Ther 2010;4:263–78.</p><p>Каратеев Д.Е., Синельникова Т.Г., Литвицкий П.Ф. Борьба с многоликим кахектином (опыт применения инфликсимаба по незарегистрированным показаниям). Науч-практич ревматол 2011;3:75–81.</p><p>Каратеев Д.Е. Ангиогенез при ревматоидном артрите. Вестн РАМН 2003;7:47–51.</p><p>Green M.J., Gough A.K., Devlin J. et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2003;42:83–8.</p><p>Moses M.A. The Regulation of neovascularization by matrix metalloproteinases and their inhibitors. Stem Cells 1997;15:180–9.</p></div><br />